Brewing Medicines with Synthetic Biology: Antheia’s Christina Smolke on Ending Drug Shortages
In this episode of the Grow Everything Biotech Podcast, Karl and Erum welcome Christina Smolke, CEO of Antheia and Professor at Stanford University, to discuss the rapid changes happening in biotech, particularly focusing on the biohacking community and decentralized science (DCI).
Synthetic Biology at Scale: Less Disruption, More Cohesion

For synthetic biology companies, scaling up means reaching out—working with government bodies, identifying partners, and securing manufacturing capacity
Antheia Secures $17 Million to Boost U.S. Production of Critical Pharmaceutical Ingredients

Antheia, a pioneering pharmaceutical ingredient manufacturer, has announced a significant $17 million funding boost aimed at transforming the supply chains of essential medicines.
Antheia Announces $17 Million in Funding for Domestic Pharmaceutical Ingredient Production

Antheia announced that it has received $17 million in funding to be used for projects focused on building domestic pharmaceutical production sites.
Antheia secures new funding to boost pharmaceutical ingredients production

The company secured funding through government project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), alongside strategic investment from In-Q-Tel and Echo
Antheia Announces New Funding to Support Domestic Production of Critical Pharmaceutical Ingredients
Company awarded government project agreement to onshore key pharmaceutical supply chains, alongside strategic investment from In-Q-Tel and Echo
Antheia CEO Keynotes at OECD Global Forum on Technology: Building our Bio Future

Last week, Antheia CEO and co-founder, Dr. Christina Smolke joined OECD’s Global Forum on Technology: Building our Bio Future as a keynote speaker. OECD (Organization for Economic Co-operation and Development) is an international organization bringing together government, academia, and industry to build global policies that foster prosperity and well-being for all. In her keynote address, […]
Chemicals Knowledge Hub: DCAT Week 2024 Andrea Conforto, VP/Biotech for CDMO at Olon and Zack McGahey, COO at Antheia
In this interview with Antheia and Olon, two leading companies in the life sciences industry, we discussed their ongoing partnership, market trends, and the future of the industry.
Future of Pharma Insights: Q&A with Olon Group

We sat down with Andrea Conforto, VP of CDMO at Olon Biotech.
PharmaSource: Antheia and Olon Extend Biomanufacturing Partnership
Antheia and Olon have announced a continuation of partnership, leveraging Olon’s fermentation infrastructure for the manufacture of Antheia’s early products